Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD).

It also covers generic medicines from Novartis' Sandoz unit that are used to treat heart failure and hypertension (amlodipine, bisoprolol, hydrochlorothiazide, furosemide and ramipril), high ...

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost ...

Results: 197 patients (66.5% women) were assigned to received amlodipine (n = 97) or hydrochlorothiazide (n = 100). 86 patients treated with amlodipine and 98 patients treated with ...

This study's principal finding that second-line treatment with a regimen that includes SPC amlodipine/valsartan formulations reduces BP, increases BP control, and improves TCVR status is critical ...